Guadecitabine clinical trials
Also written SGI-110.
How each study uses guadecitabine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
31 studies that test it; most in 2017 (8)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 4 |
| 2016 | 4 |
| 2017 | 8 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 23
Astex Pharmaceuticals, Inc. (7) · University of Southern California (3) · M.D. Anderson Cancer Center (3) · National Cancer Institute (NCI) (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · Groupe Francophone des Myelodysplasies (2) · Italian Network for Tumor Biotherapy Foundation (2) · Memorial Sloan Kettering Cancer Center (1)
Often tested with
Tested in the same studies.
Carboplatin (2) · Mocetinostat (1) · Decitabine and cedazuridine drug combination (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test guadecitabine.
- Jun 2027Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or RelapsedPhase 1/2 · University of Southern California
- Jul 2027Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.Phase 1 · Memorial Sloan Kettering Cancer Center
Studies
Open first, then newest update. How each study uses guadecitabine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 31
- Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional ChondrosarcomaActive, not recruitingPhase 2National Cancer Institute (NCI)NCT04340843Written as GuadecitabineHow we know
- Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.Active, not recruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT03220477Written as GuadecitabineHow we know
- Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or RelapsedActive, not recruitingPhase 1/2University of Southern CaliforniaNCT02935361Written as GuadecitabineHow we know
- Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder CancerActive, not recruitingPhase 1University of Southern CaliforniaNCT03257761Written as GuadecitabineHow we know
- Combination Study of Guadecitabine/ASTX727 and PembrolizumabActive, not recruitingPhase 1Royal Marsden NHS Foundation TrustNCT02998567Written as GuadecitabineHow we know
- A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney CancerTerminatedPhase 2National Cancer Institute (NCI)NCT03165721Written as SGI-110 (guadecitabine)How we know
- Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell TransplantCompletedPhase 2M.D. Anderson Cancer CenterNCT02684162Written as GuadecitabineHow we know
- Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic SyndromesCompletedPhase 2M.D. Anderson Cancer CenterNCT02131597Written as GuadecitabineHow we know
- SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)CompletedPhase 1/2Astex Pharmaceuticals, Inc.NCT01261312Written as GuadecitabineHow we know
- Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid LeukemiaCompletedPhase 3Astex Pharmaceuticals, Inc.NCT02920008Written as guadecitabineHow we know
- SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission InductionCompletedPhase 3Astex Pharmaceuticals, Inc.NCT02348489Written as SGI-110 (guadecitabine)How we know
- Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaCompletedPhase 2M.D. Anderson Cancer CenterNCT02096055Written as GuadecitabineHow we know
- Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAsCompletedPhase 3Astex Pharmaceuticals, Inc.NCT02907359Written as GuadecitabineHow we know
- SGI-110 in Combination With Carboplatin in Ovarian CancerCompletedPhase 2Astex Pharmaceuticals, Inc.NCT01696032Written as SGI-110How we know
- SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)CompletedPhase 2Astex Pharmaceuticals, Inc.NCT01752933Written as SGI-110How we know
- Guadecitabine Extension StudyTerminatedPhase 2Astex Pharmaceuticals, Inc.NCT03603964Written as GuadecitabineHow we know
- Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedPhase 2Northwestern UniversityNCT02901899Written as GuadecitabineHow we know
- Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung CancerCompletedPhase 2Shadia Jalal, MDNCT03913455Written as GuadecitabineHow we know
- A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative NeoplasmsCompletedPhase 2Weill Medical College of Cornell UniversityNCT03075826Written as SGI-110How we know
- Study of Durvalumab and Guadecitabine in Advanced Kidney CancerActive, not recruitingPhase 1/2Ajjai Alva, MDNCT03308396Written as GuadecitabineHow we know
See all 31 studies that test guadecitabine →
Given beside what is tested · 2 — guadecitabine is usual care or a partner of the new treatment
- Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedPhase 1/2National Cancer Institute (NCI)NCT03206047Written as GuadecitabineHow we know
- A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)CompletedPhase 1Hoffmann-La RocheNCT02892318Written as GuadecitabineHow we know
Codes
What other systems call guadecitabine · ClinicalTrials.gg INT006268
- MeSH (NLM) C580831guadecitabineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 2KT4YN1DP7GUADECITABINEConfirmed FDA, NLM, Wikidata
- Wikidata Q27254880guadecitabineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C95209GuadecitabineOne source FDA
- DrugBank DB11918One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C580831 | guadecitabine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 2KT4YN1DP7 | GUADECITABINE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27254880 | guadecitabine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C95209 | Guadecitabine | One source FDA |
| DrugBank | DB11918 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.